Block Grant R41AR056169

Federal Project Grant Award Summary Award Details: Abvacc, Inc. received a $638,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was issued on August 22, 2025, with a completion date of July 31, 2030, and performance will be conducted in Rockville, Maryland. Products and Services: The grant funds development of an immunotherapeutic antibody cocktail for treating...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $222,085 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco, with an award date of October 24, 2025, and completion date of November 6, 2026. The grant funds research investigating the mechanisms by which early-life exposure to skin commensal microbiota promotes immune tolerance,...

Federal Grant Award Summary New York Medical College received a $261,846 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 2, 2025, with completion targeted for June 30, 2027. The grant supports development of an intranasal protein subunit vaccine against Pseudomonas aeruginosa (PA), a gram-negative opportunistic pathogen responsible for significant healthcare-acquired...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $439,375 Project Grant on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research and development activities focused on validating S protein as a novel vaccine candidate against Group A Streptococcus (GAS), a human pathogen responsible for approximately one billion infections annually...

Federal Project Grant Summary Solaris Vaccines, Inc. received a $269,874 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025 through July 31, 2027. The award funds development and evaluation of SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine designed to address critical gaps in existing tuberculosis prevention. The vaccine uses a novel...

Federal Grant Award Summary Vanderbilt University received a $448,089 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 3, 2026, with a completion date of January 31, 2028. The award supports the development and testing of TOLEVAX, a tolerogenic vaccine platform engineered using extracellular vesicles (EVs) derived from mesenchymal stem cells (MSC-EVs) to deliver...

Federal Project Grant Award Summary New York University School of Medicine received a $836,484 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 19, 2026, with completion targeted for April 30, 2031. The project develops vectored immunoprophylaxis (VIP) utilizing adeno-associated virus (AAV) and lentiviral vectors to deliver ACE2 receptor decoy proteins as a novel...

Federal Grant Award Summary Siolta Therapeutics Inc. received a $529,498 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 5, 2025, through July 31, 2028. The award supports the development of STMC-105, a multispecies live biotherapeutic product (LBP) designed to prevent recurrent bacterial vaginosis (RBV) in women by restoring protective lactobacillus...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, through August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) flu vaccine candidate designed for transcutaneous (intradermal) immunization. The project leverages Via Therapeutics' proprietary thin-film...